Most Recent Links
Follow us on Facebook and Twitter, or subscribe to our mailing list, to receive news updates. Learn more.
Laura Beil People who undergo gastric bypass surgery are more likely to experience a remission of their diabetes than patients who receive a gastric sleeve or intensive management of diet and exercise, according to a new study. Bypass surgery had already shown better results for diabetes than other weight-loss methods in the short term, but the new research followed patients for five years. “We knew that surgery had a powerful effect on diabetes,” says Philip Schauer of the Bariatric & Metabolic Institute at the Cleveland Clinic. “What this study says is that the effect of surgery is durable.” The results were published online February 15 in the New England Journal of Medicine. The study followed 134 people with type 2 diabetes for five years in a head-to-head comparison of weight-loss methods. At the end of that time, two of 38 patients who only followed intensive diet and exercise plans were no longer in need of insulin to manage blood sugar levels. For comparison, 11 of 47 patients who had a gastric sleeve, which reduces the size of the stomach, and 14 of 49 who underwent gastric bypass, a procedure that both makes the stomach smaller and shortens digestion time, did not need the insulin anymore. In general, patients who had been diabetic for fewer than eight years were more likely to be cured, Schauer says. Even those surgical patients who still needed to take insulin had greater weight loss and lower median glucose levels than others in the study. This study was also one of the few to show that bariatric surgery could help those with only mild obesity, defined as a body mass index between 27 and 34. How bariatric surgery might improve diabetes is still unknown, but scientists have pointed to effects on the body’s metabolism (SN: 8/24/13, p. 14) and gut microbes (SN: 9/5/15, p. 16). |© Society for Science & the Public 2000 - 2016.
Link ID: 23235 - Posted: 02.16.2017
Sarah Jane Tribble In response to outrage from patients and lawmakers, Marathon Pharmaceuticals has delayed the launch of an $89,000 drug for Duchenne muscular dystrophy. The company had announced the annual list price for Emflaza, which is a steroid, after the Food and Drug Administration approved the drug Thursday. Emflaza is approved as an orphan drug, which means it is intended to treat a rare disease. Duchenne is an inherited disorder that causes muscles to become weak. There is no cure for the condition, which mainly affects boys, but some drugs, including Emflaza, are used to lessen symptoms. For years, many American patients have imported deflazacort, the generic version of Emflaza, for about $1,200 a year. But because the medicine wasn't approved in the U.S., the cost of the medicine wasn't typically covered by insurers. That contrast in price between became a flash point Monday as Sen. Bernie Sanders, I-Vt., and Rep. Elijah Cummings, D-Md., sent a letter to Marathon on Monday morning demanding answers about the $89,000 price for a drug that isn't new. It has been used routinely by Duchenne patients in the U.S. since at least 2005. "We believe Marathon is abusing our nation's 'orphan drug' program, which grants companies seven years of market exclusivity to encourage research into new treatments for rare diseases — not to provide companies like Marathon with lucrative market exclusivity rights for drugs that have been available for decades," Sanders and Cummings wrote. Marathon said FDA approval would help more patients get the drug. © 2017 npr
Keyword: Movement Disorders
Link ID: 23234 - Posted: 02.15.2017
By Jesse Singal Those who advocate for sound, evidence-based research about autism are extremely alarmed about Donald Trump, and for good reason: In addition to Trump’s ties to Andrew Wakefield, the disgraced British doctor whose debunked research helped fuel the false idea of links between childhood vaccines and autism, Robert F. Kennedy Jr., a notorious anti-vaxxer himself, told reporters back in January that Trump planned to tap him as chair of a commission on “vaccine safety.” There is no question at this point that Trump has significant connections to a pseudoscientific medical movement that spreads dangerous, disproven ideas. Today, Trump gave nervous observers yet more reason to worry. It occurred at a White House event in which Trump and Secretary of Education Betsy DeVos met with a bunch of educators. Trump seemed to fixate, for a moment, on one educator named Jane (her last name is hard to make out) after she explained that she is the principal of a special education center in Virginia. The sequence starts at about 5:38 in this video: After Jane noted that many of her students have autism, Trump asked, “Have you seen a big increase in the autism, with the children?” Jane replied in the affirmative, but seemed to couch her response as being more about an increase in demand for services — she didn’t explicitly agree there’s been a big increase in the overall rate. Trump continued: “So what’s going on with autism? When you look at the tremendous increase, it’s really — it’s such an incredible — it’s really a horrible thing to watch, the tremendous amount of increase. Do you have any idea? And you’re seeing it in the school?” Jane replied — again, in a way that seems a bit noncommittal vis-à-vis Trump’s claim — that the rate of autism is something like 1-in-66 or 1-in-68 children. To which Trump responds: “Well now, it’s gotta be even lower [presumably meaning higher, rate-wise] than that, which is just amazing — well, maybe we can do something.” (Jane had the rate right, and Trump is incorrect that it has crept higher.) © 2017, New York Media LLC.
Link ID: 23233 - Posted: 02.15.2017
By Amitha Kalaichandran, When pain researcher Diane Gromala recounts how she started in the field of virtual reality, she seems reflective. She had been researching virtual reality for pain since the early 1990s, but her shift to focusing on how virtual reality could be used for chronic pain management began in 1999, when her own chronic pain became worse. Prior to that, her focus was on VR as entertainment. Gromala, 56, was diagnosed with chronic pain in 1984, but the left-sided pain that extended from her lower stomach to her left leg worsened over the next 15 years. "Taking care of my chronic pain became a full-time job. So at some point I had to make a choice — either stop working or charge full force ahead by making it a motivation for my research. You can guess what I chose," she said. Diane Gromala Pain researcher Diane Gromala found that taking care of her own chronic pain became 'a full-time job.' (Pain studies lab at Simon Fraser University) Now she's finding that immersive VR technology may offer another option for chronic pain, which affects at least one in five Canadians, according to a 2011 University of Alberta study. "We know that there is some evidence supporting immersive VR for acute pain, so it's reasonable to look into how it could help patients that suffer from chronic pain." Gromala has a PhD in human computer interaction and holds the Canada Research Chair in Computational Technologies for Transforming Pain. She also directs the pain studies lab and the Chronic Pain Research Institute at Simon Fraser University in Burnaby, B.C. ©2017 CBC/Radio-Canada.
By GINA KOLATA Dr. James Weinstein, a back pain specialist and chief executive of Dartmouth-Hitchcock Health System, has some advice for most people with lower back pain: Take two aspirin and don’t call me in the morning. On Monday, the American College of Physicians published updated guidelines that say much the same. In making the new recommendations for the treatment of most people with lower back pain, the group is bucking what many doctors do and changing its previous guidelines, which called for medication as first-line therapy. Dr. Nitin Damle, president of the group’s board of regents and a practicing internist, said pills, even over-the-counter pain relievers and anti-inflammatories, should not be the first choice. “We need to look at therapies that are nonpharmacological first,” he said. “That is a change.” The recommendations come as the United States is struggling with an epidemic of opioid addiction that often begins with a simple prescription for ailments like back pain. In recent years, a number of states have enacted measures aimed at curbing prescription painkillers. The problem has also led many doctors around the country to reassess prescribing practices. The group did not address surgery. Its focus was on noninvasive treatment.The new guidelines said that doctors should avoid prescribing opioid painkillers for relief of back pain and suggested that before patients try anti-inflammatories or muscle relaxants, they should try alternative therapies like exercise, acupuncture, massage therapy or yoga. Doctors should reassure their patients that they will get better no matter what treatment they try, the group said. The guidelines also said that steroid injections were not helpful, and neither was acetaminophen, like Tylenol, although other over-the-counter pain relievers like aspirin, naproxen or ibuprofen could provide some relief. © 2017 The New York Times Company
Keyword: Pain & Touch
Link ID: 23231 - Posted: 02.15.2017
Elizabeth Eaton A prehistoric marine reptile may have given birth to its young alive. A fossil from South China may be the first evidence of live birth in the animal group Archosauromorpha, scientists report February 14 in Nature Communications. Today Archosauromorpha is represented by birds and crocodiles — which both lay eggs. Whether this fossil really is the first evidence of live birth in Archosauromorpha depends on how another group of semiaquatic animals is classified, says Michael Caldwell, a vertebrate paleontologist with the University of Alberta in Canada. Placement of Choristodera, a now-extinct group that included a freshwater reptile that gave live birth, remains murky, with some researchers putting them with Archosauromorpha and others with a group that includes snakes and lizards. “Our discovery is the first of live birth in reptiles with undoubted archosauromorph affinity,” says Jun Liu, a paleontologist at Hefei University of Technology in China. Researchers have speculated that the biology of archosauromorphs prevented their reproductive traits from evolving, says study coauthor Chris Organ, an evolutionary biologist with Montana State University in Bozeman. This find may disprove that view. “Ancestrally, the science suggests that live birth is not absolutely prohibited,” Organ says. Even though birds and crocodiles haven’t yet evolved to give life birth, this discovery suggests that it’s possible. |© Society for Science & the Public 2000 - 2016
By Rachael Lallensack Goats know who their real friends are. A study published today in Royal Society Open Science shows that the animals can recognize what other goats look like and sound like, but only those they are closest with. Up until the late 1960s, the overwhelming assumption was that only humans could mentally keep track of how other individuals look, smell, and sound—what scientists call cross-modal recognition. We now know that many different kinds of animals can do this like horses, lions, crows, dogs, and certain primates. Instead of a lab, these researchers settled into Buttercups Sanctuary for Goats in Boughton Monchelsea, U.K., to find out whether goats had the ability to recognize each other. To do so, they first recorded the calls of individual goats. Then, they set up three pens in the shape of a triangle in the sanctuary’s pasture. Equidistant between the two pens at the base of the triangle was a stereo speaker, camouflaged as to not distract the goat participants. A “watcher” goat stood at the peak of the triangle, and the two remaining corners were filled with the watcher’s “stablemate” (they share a stall at night) and a random herd member. Then, the team would play either the stablemate’s or the random goat’s call over the speaker and time how long it took for the watcher to match the call with the correct goat. They repeated this test again, but with two random goats. The researchers found that the watcher goat would look at the goat that matched the call quickly and for a longer time, but only in the test that included their stablemate. The results indicate that goats are not only capable of cross-modal recognition, but that they might also be able to use inferential reasoning, in other words, process of elimination. Think back to the test: Perhaps when the goat heard a call that it knew was not its pal, it inferred that it must have been the other one. © 2017 American Association for the Advancement of Science.
Jon Hamilton Researchers have created mice that appear impervious to the lure of cocaine. Even after the genetically engineered animals were given the drug repeatedly, they did not appear to crave it the way typical mice do, a team reports in Nature Neuroscience. "They didn't keep going into the room where they received the cocaine and they seemed to be just as happy exploring all around the cage," says Shernaz Bamji, a professor in the Department of Cellular and Physiological Sciences at the University of British Columbia in Vancouver. "Addiction is a form of learning," Bamji says. And somehow, these mice never learned to associate the pleasurable feelings produced by cocaine with the place where they received the drug. The result was startling because the scientists thought these mice would be especially susceptible to addiction. "We repeated the experiment several times to see if we had made a mistake," Bamji says. The reason for the team's surprise had to do with proteins that affect learning. The animals had been genetically engineered to produce high levels of proteins called cadherins in the brain's "reward circuit," which plays an important role in addiction. And genetic studies have suggested that people with high levels of cadherins are more susceptible to drug addiction. Cadherins act a bit like glue, binding cells together. Usually this glue enhances learning by strengthening the connections, or synapses, between brain cells. © 2017 npr
Ian Sample Science editor Children who are born very prematurely are at greater risk of developing mental health and social problems that can persist well into adulthood, according to one of the largest reviews of evidence. Those with an extremely low birth weight, at less than a kilogram, are more likely to have attention disorders and social difficulties as children, and feel more shyness, anxiety and depression as adults, than those born a healthy weight. The review draws on findings from 41 published studies over the past 26 years and highlights the need for doctors to follow closely how children born very prematurely fare as they become teenagers and adults. “It is important that families and doctors be aware of the potential for these early-emerging mental health problems in children born at extremely low birth weight, since at least some of them endure into adulthood,” said Karen Mathewson, a psychologist at McMaster University in Ontario. Improvements in neonatal care in the past two decades mean that more children who are born very prematurely now survive. In a healthy pregnancy, a baby can reach 1kg (a little more than 2lbs) within 27 weeks, or the end of the second trimester. The study, which involves data from 13,000 children in 12 different countries, follows previous research that found a greater tendency for very low birth weight children to have lower IQs and autism and more trouble with relationships and careers as they reach adulthood and venture into the world. © 2017 Guardian News and Media Limited
By Andy Coghlan It’s as if a switch has been flicked. Evidence is mounting that chronic fatigue syndrome (CFS) is caused by the body swapping to less efficient ways of generating energy. Also known as ME or myalgic encephalomyelitis, CFS affects some 250,000 people in the UK. The main symptom is persistent physical and mental exhaustion that doesn’t improve with sleep or rest. It often begins after a mild infection, but its causes are unknown. Some have argued that CFS is a psychological condition, and that it is best treated through strategies like cognitive behavioural therapy. But several lines of investigation are now suggesting that the profound and painful lack of energy seen in the condition could in many cases be due to people losing their ability to burn carbohydrate sugars in the normal way to generate cellular energy. Instead, the cells of people with CFS stop making as much energy from sugar as usual, and start relying more on lower-yielding fuels, such as amino acids and fats. This kind of metabolic switch produces lactate, which can cause pain when it accumulates in muscles. Together, this would explain both the shortness of energy, and why even mild exercise can be exhausting and painful. © Copyright Reed Business Information Ltd.
Link ID: 23226 - Posted: 02.14.2017
By BENEDICT CAREY The number of retirement-age Americans taking at least three psychiatric drugs more than doubled between 2004 and 2013, even though almost half of them had no mental health diagnosis on record, researchers reported on Monday. The new analysis, based on data from doctors’ office visits, suggests that inappropriate prescribing to older people is more common than previously thought. Office visits are a close, if not exact, estimate of underlying patient numbers. The paper appears in the journal JAMA Internal Medicine. Geriatric medical organizations have long warned against overprescribing to older people, who are more susceptible to common side effects of psychotropic drugs, such as dizziness and confusion. For more than 20 years, the American Geriatrics Society has published the so-called Beers Criteria for potentially inappropriate use, listing dozens of drugs and their mutual interactions. In that time, prescription rates of drugs like antidepressants, sleeping pills and painkillers nonetheless generally increased in older people, previous studies have found. The new report captures one important dimension, the rise in so-called polypharmacy — three drugs or more — in primary care, where most of the prescribing happens. Earlier research has found that elderly people are more likely to be on at least one psychiatric drug long term than younger adults, even though the incidence of most mental disorders declines later in life. “I was stunned to see this, that despite all the talk about how polypharmacy is bad for older people, this rate has doubled,” said Dr. Dilip Jeste, a professor of psychiatry and neurosciences at the University of California, San Diego, who was not involved in the new work. © 2017 The New York Times Company
By Virginia Morell Strange as it might seem, not all animals can immediately recognize themselves in a mirror. Great apes, dolphins, Asian elephants, and Eurasian magpies can do this—as can human kids around age 2. Now, some scientists are welcoming another creature to this exclusive club: carefully trained rhesus monkeys. The findings suggest that with time and teaching, other animals can learn how mirrors work, and thus learn to recognize themselves—a key test of cognition. “It’s a really interesting paper because it shows not only what the monkeys can’t do, but what it takes for them to succeed,” says Diana Reiss, a cognitive psychologist at Hunter College in New York City, who has given the test to dolphins and Asian elephants in other experiments. The mirror self-recognition test (MSR) is revered as a means of testing self-awareness. A scientist places a colored, odorless mark on an animal where it can’t see it, usually the head or shoulder. If the animal looks in the mirror and spontaneously rubs the mark, it passes the exam. Successful species are said to understand the concept of “self” versus “other.” But some researchers wonder whether failure is simply a sign that the exam itself is inadequate, perhaps because some animals can’t understand how mirrors work. Some animals—like rhesus monkeys, dogs, and pigs—don’t recognize themselves in mirrors, but can use them to find food. That discrepancy puzzled Mu-ming Poo, a neurobiologist at the Shanghai Institutes for Biological Sciences in China, and one of the study’s authors. “There must be some transition between that simple mirror use and recognizing yourself,” he says. © 2017 American Association for the Advancement of Science.
Richard A. Friedman Psychedelics, the fabled enlightenment drugs of the ’60s, are making a comeback — this time as medical treatment. A recent study claimed that psilocybin, a mushroom-derived hallucinogenic, relieves anxiety and depression in people with life-threatening cancer. Anecdotal reports have said similar things about so-called microdoses of LSD. The allure is understandable, given the limits of our treatments for depression and anxiety. About a third of patients with major depression don’t get better, even after several trials of different antidepressants. But I fear that in our desire to combat suffering, we will ignore the potential risks of these drugs, or be seduced by preliminary research that seems promising. This appears to be the case with the new psilocybin study, which has some serious design flaws that cast doubt on the results (and which the authors mention briefly). The study, done at New York University School of Medicine, examined a very small number of people with cancer in a “crossover” design in which each subject served as her own control, sequentially receiving doses of psilocybin and the control drug niacin, in random order. (Another recent study of psilocybin, done at Johns Hopkins University, used a similar crossover design.) Psilocybin, being a hallucinogen, has immediately recognizable mental effects, so subjects would almost certainly know when they were getting it compared with niacin, a vitamin that causes flushing but has no discernible effect on mood or thinking. This makes it hard to know if subjects got better because of the psilocybin, or because of a placebo effect. The design also means that subjects who got psilocybin first could have had a “carry-over effect” from the drug when they received niacin. In other words, they might still have been under the influence, contaminating the control condition. © 2017 The New York Times Company
By Sam Wong Here’s looking at you, squid. Cock-eyed squid have one huge, bulging eye and another normal-sized eye, but the reason has remained a mystery. Now we have an answer. Kate Thomas of Duke University in North Carolina studied 161 videos of the creatures collected over 26 years by remotely operated submarines in Monterey Bay, California. The findings provide the first behavioural evidence that the two eyes are adapted to look in different directions. The large one points upwards to spot prey silhouetted against the sky. The smaller one points downwards to spot bioluminescent organisms against the darkness below. The squid, from the histioteuthid family, live at depths of 200 to 1000 metres, where little light penetrates. The videos show that the squid normally swims with its tail end pointing upwards, but tilted so the large eye is consistently oriented towards the sky. Based on measurements of the eyes and the light levels they would be exposed to, Thomas and her colleagues calculated that having a big upward-pointing eye greatly improves visual perception, while a downward-pointing eye would gain little from being large. “That gives you the context for how this trait might have evolved,” says Thomas. Some of the squid’s prey, such as lanternfish and shrimp, have luminescent undersides so they are camouflaged against the sunlight when seen from below. Yellow pigmentation in the lens of the squid’s large eye may help it distinguish between sunlight and bioluminescence. © Copyright Reed Business Information Ltd.
Moises Velasquez-Manoff This Valentine’s Day, as you bask in the beauty of your beloved, don’t just thank his or her genes and your good fortune; thank microbes. Research on the microbes that inhabit our bodies has progressed rapidly in recent years. Scientists think that these communities, most of which live in the gut, shape our health in myriad ways, affecting our vulnerability to allergic diseases like hay fever, how much weight we put on, our susceptibility to infection and maybe even our moods. They can also, it seems, make us sexy. Susan Erdman, a microbiologist at M.I.T., calls it the “glow of health.” The microbes you harbor, she argues, can make your skin smooth and your hair shiny; they may even put a spring in your step. She stumbled on the possibility some years ago when, after feeding mice a probiotic microbe originally isolated from human breast milk, a technician in her lab noticed that the animals grew unusually lustrous fur. Further observation of males revealed thick skin bristling with active follicles, elevated testosterone levels and oversize testicles, which the animals liked showing off. Microbes had transformed these animals into rodent heartthrobs. When given to females, the probiotic also prompted deeper changes. Levels of a protein called interleukin 10, which helps to prevent inflammatory disease and ensure successful pregnancy, went up, as did an important hormone called oxytocin. Oxytocin, often called the love hormone, helps mammals bond with one another. Our bodies may release it when we kiss (and mean it), when women breast-feed, even when people hang out with good friends. And the elevated oxytocin Dr. Erdman saw had important effects during motherhood. Some of the mice in her studies were eating a high-fat, high-sugar diet — junk-foody fare that’s known to shift the microbiome into an unhealthy state. Not surprisingly perhaps, mothers that didn’t imbibe the probiotics were less caring and tended to neglect their pups. But mothers that had high oxytocin thanks to the probiotic were nurturing and reared their pups more successfully. © 2017 The New York Times Company
Patti Neighmond It's tough to be a teenager. Hormones kick in, peer pressures escalate and academic expectations loom large. Kids become more aware of their environment in the teen years — down the block and online. The whole mix of changes can increase stress, anxiety and the risk of depression among all teens, research has long shown. But a recent study published in the journal Pediatrics suggests many more teenage girls in the U.S. may be experiencing major depressive episodes at this age than boys. And the numbers of teens affected took a particularly big jump after 2011, the scientists note, suggesting that the increasing dependence on social media by this age group may be exacerbating the problem. Psychiatrist Ramin Mojtabai and colleagues at Johns Hopkins University Bloomberg School of Public Health wanted to know whether rates of depression among teens had increased over the past decade. They analyzed federal data from interviews with more than 172,000 adolescents. Between 2005 and 2014, the scientists found, rates of depression went up significantly — if extrapolated to all U.S. teens it would work out to about a half million more depressed teens. What's more, three-fourths of those depressed teens in the study were girls. The findings are just the latest in a steady stream of research showing that women of all ages experience higher rates of depression compared to men, says psychologist and author Catherine Steiner-Adair. And no wonder, she says — despite gains in employment, education and salary, women and girls are still "continually bombarded by media messages, dominant culture, humor and even political figures about how they look — no matter how smart, gifted, or passionate they are." © 2017 npr
By JANE E. BRODY “Bariatric surgery is probably the most effective intervention we have in health care,” says Laurie K. Twells, a clinical epidemiologist at Memorial University of Newfoundland. She bases this bold claim on her experience with seriously obese patients and a detailed analysis of the best studies yet done showing weight-loss surgery’s ability to reverse the often devastating effects of being extremely overweight on health and quality of life. “I haven’t come across a patient yet who wouldn’t recommend it,” Dr. Twells said in an interview. “Most say they wish they’d done it 10 years sooner.” She explained that the overwhelming majority of patients who undergo bariatric surgery have spent many years trying — and failing — to lose weight and keep it off. And the reason is not a lack of willpower. “These patients have lost hundreds of pounds over and over again,” Dr. Twells said. “The weight that it takes them one year to lose is typically back in two months,” often because a body with longstanding obesity defends itself against weight loss by drastically reducing its metabolic rate, an effect not seen after bariatric surgery, which permanently changes the contours of the digestive tract. In reviewing studies that followed patients for five to 25 years after weight-loss surgery, Dr. Twells and colleagues found major long-lasting benefits to the patients’ health and quality of life. Matched with comparable patients who did not have surgery, those who did fared much better physically, emotionally and socially. They rated themselves as healthier and were less likely to report problems with mobility, pain, daily activities, social interactions and feelings of depression and anxiety, among other factors that can compromise well-being. © 2017 The New York Times Company
Link ID: 23219 - Posted: 02.13.2017
By Abigail Zuger, M.D. It was in 2011 that the Centers for Disease Control first drew public attention to the ongoing nationwide opioid crisis. Much earnest commentary has explored the roots of this new killer epidemic since then, focusing on the broad highway between heroin and pain pills, and the online pharmacies, pill mills, and bad-apple doctors who fueled the two-way traffic and enabled catastrophe. Forgive me for rolling my eyes. Anyone with a prescription pad and a shred of common sense saw this whole thing coming down the pike decades ago, a speeding 18-wheeler, tires squealing, no brakes. Furthermore, it has long been clear that while the bad medical apples certainly did their share of damage, there is not a health policy guru or medical school dean in the country whose sins of omission and commission are not also partly responsible. Call it an epidemic of unconscious collusion or, as Dr. Anna Lembke bluntly states, a nation’s doctors “trapped in a system gone mad.” In less than 200 pages, this may be the most important medical book of the decade for finally getting the story of the opioid epidemic exactly right. As far as I am concerned, “Drug Dealer, M.D.,” in less than 200 unassuming, readable, and carefully referenced pages, may be the most important medical book of the decade for finally getting the story of this epidemic exactly right. And it’s not the medical bad apples Lembke is talking about in her title — it’s every doctor in the country. Copyright 2017 Undark
By KENNETH CHANG Sir Peter Mansfield, who shared a Nobel Prize for discoveries that underpinned the invention of magnetic resonance imaging, the method of peering inside the human body that revolutionized medicine, died on Wednesday. He was 83. The University of Nottingham in England, where Dr. Mansfield had been a professor of physics, announced his death but not did say where he died. He lived in England. Magnetic resonance imaging, or M.R.I., has enabled doctors to diagnose and examine injuries to ligaments, bones and organs without cutting open the body or risking the radiation dangers of X-rays. “It’s hugely important,” said Charles P. Slichter, an emeritus physics professor at the University of Illinois at Urbana-Champaign. “It’s such an all-pervasive technique.” Dr. Mansfield worked in his laboratory as a postdoctoral researcher in the 1960s. Dr. Mansfield was awarded the Nobel Prize in Physiology or Medicine in 2003, along with Paul C. Lauterbur, a professor at the University of Illinois at Urbana-Champaign. The two had worked independent of each other in studying magnetic resonance imaging. Their research proceeded from an understanding that the nuclei of most atoms act as tiny magnets that line up when placed in a magnetic field. If the field is set at a specific strength, the atoms can absorb and emit radio waves. Scientists initially used the technique, called nuclear magnetic resonance, or N.M.R., to study atoms and molecules, deducing properties from the emitted waves. In his early research, Dr. Mansfield developed N.M.R. techniques to study crystals. Later, in 1972, as he worked to refine and sharpen N.M.R. data, he had a conversation with two colleagues about what applications such advances might lead to. He soon realized that if an object were placed in a nonuniform magnetic field — one that is stronger at one end than the other — scientists might be able to piece together a three-dimensional image of its atomic structure. © 2017 The New York Times Company
Keyword: Brain imaging
Link ID: 23217 - Posted: 02.13.2017
By Matt Blois A ruthless killer may soon help brain cancer patients. The rabies virus, which kills tens of thousands of people a year, has a rare ability to enter nerve cells and use them as a conduit to infect brain tissue. Now, scientists are trying to mimic this strategy to ferry tumor-killing nanoparticles into brain tumors. So far the approach has been shown to work only in mice. If successful in people, these nanoparticles could one day help doctors send treatment directly to tumors without harming healthy cells. The rabies virus, transmitted largely through the bites of infected animals, has evolved over thousands of years to hijack nerve cells, which it uses to climb from infected muscle tissue into the brain. That allows it to bypass a major hurdle: the blood-brain barrier, a selective membrane that keeps out most pathogens that travel through the bloodstream. But the barrier also prevents treatments—like cancer drugs—from reaching infected cells, limiting options for patients. To get around this problem, scientists are looking to the virus for inspiration. Already, researchers have packaged cancer-fighting drugs into nanoparticles coated with part of a rabies surface protein that lets the virus slip into the central nervous system. Now, a team of researchers from Sungkyunkwan University in Suwon, South Korea, has taken things one step further. Nanoparticle expert Yu Seok Youn and his team have engineered gold particles so that they have the same rodlike shape and size as the virus. The nanoparticle’s shape gives it more surface area than spherical particles, improving the surface protein’s ability to bind with receptors on nerve cells that serve as a gateway to the nervous system. The particles don’t carry any drugs, but the tiny gold rods readily absorb laser light, which heats them up and kills surrounding tissue. © 2017 American Association for the Advancement of Science.